Does Insurance Cover Zepbound or Wegovy? Aetna, Cigna, UHC, BCBS, Kaiser, Tricare and Medicare, Compared

"Does my insurance cover it" has a different answer depending on which insurance, which specific plan under that insurance, and which reason you're taking it. That's not a hedge — it's the literal structure every major payer builds into its own coverage policy, and it's worth reading each one's actual document instead of a generic yes-or-no summary. Here's what eight of the most-searched payers currently publish, sourced directly to each.

Aetna: covers it in some states and plans, under a program that isn't universal

Aetna's current pharmacy clinical policy bulletin for anti-obesity agents lists Wegovy and Zepbound alongside Saxenda, Contrave, Qsymia and Xenical as precertification-eligible drugs, approved against the same FDA-label logic every insurer uses: an initial BMI of 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension, dyslipidemia or type 2 diabetes¹. The detail worth noticing is in the document's own title: it's explicitly scoped "ONLY for Specific States," and Aetna maintains multiple parallel versions of this same policy for different states and plan types. That's evidence in itself that there's no single "does Aetna cover Zepbound" answer — whether precertification is even available, and on what terms, depends on which version of Aetna's policy your specific plan runs.

Cigna: a written exclusion for many plans, and per-indication rules when it isn't excluded

Cigna's own current drug coverage policy states this more bluntly than most insurers publish anywhere public: "Weight loss medications are specifically excluded under many benefit plans," both employer-group and individual/family, and instructs reviewers to check the member's specific benefit document before assuming anything². Where a plan doesn't exclude the class, Cigna's policy splits the same drugs by indication exactly the way federal rules do: Wegovy is reviewed separately for weight reduction (with obesity or overweight-plus-comorbidity), for reducing cardiovascular event risk in adults with established cardiovascular disease, and for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis; Zepbound is reviewed separately, under its own criteria, for moderate-to-severe obstructive sleep apnea in adults with obesity². In practice, "does Cigna cover Zepbound" and "does Cigna cover Zepbound for sleep apnea" are two different questions with two different answers on the same card.

UnitedHealthcare: an opt-in employer program with its own sleep-apnea and heart-risk carve-outs

UnitedHealthcare's current Pharmacy Clinical Pharmacy Program for weight-loss and appetite-suppression medications says plainly that it's optional: "This is an optional program that is put in place for clients or businesses that have elected to cover weight loss products with Prior Authorization/Notification"³ — whether it applies to you depends on what your specific employer bought, not on a fixed UnitedHealthcare default. Inside that program, initial Zepbound authorization requires one of: general appetite suppression/weight loss, or moderate-to-severe obstructive sleep apnea specifically³; Wegovy's separate qualifying uses add cardiovascular-risk reduction and MASH. Every path still requires the standard BMI ≥30 (or ≥27 with a documented comorbidity) plus lifestyle-modification adjunct.

Blue Cross Blue Shield / Anthem: there is no single "BCBS policy" — that's the real answer

This is the payer where the honest answer is structural rather than a lookup. Blue Cross Blue Shield isn't one insurer; it's a federation of roughly three dozen independent, separately operated regional companies (Anthem is the Blues licensee across several states), each running its own formulary, its own clinical criteria and its own state-specific benefit mandates. Anthem publishes a standing clinical-criteria library and a drug-list/formulary lookup specifically because the answer changes by state and by plan⁴ — there's no version of this article that could give you one true Blues answer without it being wrong for a large share of readers. If your card says any Blues name, the reliable move is pulling your specific regional company's own formulary or clinical-criteria document, not a national generalization.

Kaiser Permanente: a closed system, genuinely less publicly documented

Kaiser runs its own integrated pharmacy rather than routing through a commercial PBM formulary the way Aetna, Cigna and UnitedHealthcare do, and its Zepbound/Wegovy coverage decisions are made by Kaiser's own regional Pharmacy & Therapeutics process — not published at the same level of public, citable detail as the clinical-policy documents above. No current public source states a single Kaiser-wide answer either way, and inventing one to fill the gap would be less accurate than saying so plainly: if you're a Kaiser member, your region's member portal or your plan's Evidence of Coverage is the only reliable check.

Tricare: it covers weight-loss use — but you pay for all of it yourself

This is the most counterintuitive answer of the eight. TRICARE's own FAQ page confirms it covers Wegovy, Saxenda and Zepbound for weight management under specific plan types once clinical criteria, a network-provider prescription, and prior authorization/medical-necessity paperwork are met — but adds, in its own words: "You will pay 100% of the cost for your weight loss drugs even if you have an approved prior authorization"⁵. That's a materially different arrangement from the same molecules prescribed for type 2 diabetes: TRICARE covers Ozempic, Mounjaro, Victoza and Trulicity for diabetes with standard cost-sharing, no all-out-of-pocket clause attached⁵. "Does TRICARE cover Wegovy" is technically yes; "will TRICARE pay for it" is a separate question with a no, specific to the weight-loss indication.

Medicare: yes for sleep apnea today, a new $50 bridge for weight-loss-only starting mid-2026

Traditional Medicare Part D has never covered a GLP-1 for weight loss alone — see our full breakdown of the underlying federal statute — but that exclusion has always been narrower than "no GLP-1 coverage at all." CMS's own current guidance states directly that type 2 diabetes, moderate-to-severe obstructive sleep apnea, and MASH with moderate-to-advanced liver fibrosis "are eligible for Part D coverage"⁶ — meaning a Zepbound prescription written for diagnosed sleep apnea is a standard Part D pharmacy claim today, not a special exception. What changes in 2026 is the weight-loss-only case specifically: CMS's Medicare GLP-1 Bridge, a demonstration running July 1, 2026 through December 31, 2027, lets eligible beneficiaries access Wegovy, Zepbound (KwikPen formulation only) and Foundayo for weight management at a $50 monthly copay, processed outside normal Part D claims flow⁶⁷. It's explicitly not for people who already qualify under diabetes, sleep apnea or MASH — those beneficiaries stay on their regular Part D pathway; the Bridge exists specifically for the weight-loss-only population Part D has excluded all along.

The one number that ties all of this together

If it feels like coverage keeps landing on "it depends," that's not this article dodging the question — it's the documented reality. A KFF analysis of federal Marketplace plan data found Wegovy, approved solely for weight loss, covered by just 1% of ACA Marketplace prescription drug plans, versus 82% for Ozempic, the same active ingredient approved for diabetes — and of the few plans that do cover a weight-loss-approved GLP-1, all required prior authorization⁸. Separate KFF research on employer-sponsored coverage shows the trend moving toward more coverage among large employers year over year, but from a low base, and with plenty of employers actively weighing whether to add, narrow or drop it⁹. The indication you're prescribed for, more than the insurer's name on your card, is usually the bigger lever.

What to actually do with this

Pull your own plan document or formulary — member portal, HR benefits page, or a call to the number on your card — rather than trusting any payer generalization, this article's included; policies change and vary by employer group even within one insurer. If your prescription is for sleep apnea, cardiovascular risk reduction, or MASH rather than weight loss alone, say so explicitly when you ask, since several payers above process that as a materially different (and more often covered) claim. For the mechanics of what a prior-authorization request actually needs once you know your plan's stance, see GLP-1 insurance coverage and prior authorization, explained; for the federal rules behind Medicare and Medicaid specifically, see Medicare, Medicaid, and HSA/FSA: the GLP-1 rules the federal government actually sets. If coverage genuinely isn't available on your plan, price the cash-pay routes in what a GLP-1 costs without insurance before assuming the drug is out of reach. The policy documents behind this article are indexed in our research library. Not medical or insurance advice — see our medical disclaimer and confirm your own plan's current rules directly with your insurer or benefits administrator.